Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in September.

  • On Wednesday September 3, 2025, at 1:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Cantor Global Healthcare Conference in New York, NY.

  • On Tuesday September 9, 2025, at 9:00 AM EDT, Dr. Walker will provide a corporate presentation during the H.C. Wainwright 27 th Annual Global Investment Conference in New York, NY.

Live and archived webcasts of both events will be accessible on the Events page of https://www.aclaristx.com/ . The webcasts will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn .

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ACRS
The Conversation (0)
Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Standard Uranium Executes Definitive Agreement to Option Rocas Uranium Project and Initiates Inaugural Exploration Program

Standard Uranium Executes Definitive Agreement to Option Rocas Uranium Project and Initiates Inaugural Exploration Program

Standard Uranium Ltd. (TSXV: STND,OTC:STTDF) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce that it has signed a definitive property option agreement (the "Option Agreement"), dated September 26, 2025, with Collective Metals Inc. (CSE: COMT) (the "Optionee"), an arms-length party. Pursuant to the Option Agreement, the Optionee has been granted the option (the "Option") to acquire a seventy-five percent interest in the 4,002-hectare Rocas Project ("Rocas" or the "Project") located in the eastern Athabasca Basin region (Figure 1).

Rocas Project Highlights:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
VVC - Commencement of Central Kansas Uplift Project

VVC - Commencement of Central Kansas Uplift Project

VVC Exploration Corporation, dba VVC Resources ("VVC" or the "Company") (TSX-V: VVC; OTC: VVCVF) today announces its strategic development of the Central Kansas Uplift ("CKU") Project, an initiative being advanced through VVC's wholly owned subsidiary, Plateau Helium Corporation ("PHC"). The CKU Project targets helium-rich natural gas within multiple stacked reservoirs in Rush and Pawnee Counties, Kansas, where PHC has assembled a meaningful lease position and identified multiple well development locations. The CKU Project is a very mature exploration area with thousands of historic wells drilled. These wells provide a tremendous volume of geologic, engineering, and production data that is used to guide and de-risk PHC's development plans.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
American Uranium Limited  Lo Herma Resource Expansion Drilling Approved

American Uranium Limited Lo Herma Resource Expansion Drilling Approved

Perth, Australia (ABN Newswire) - American Uranium Limited (ASX:AMU,OTC:GTRIF) (OTCMKTS:GTRIF) is pleased to advise that The State of Wyoming's Land Quality Division (LQD) has now approved AMU's resource development drilling program. The first phase of drilling is expected to commence during the coming quarter with further details the timing of the drilling and hydrogeolical testing to be provided in due course.


Highlights

- Lo Herma resource expansion and infill drilling campaign approval received

- Phase one drilling to focus on resource expansion and is expected to start Q4 2025

AMU CEO and Executive Director Bruce Lane commented:

"We are delighted that our upcoming resource expansion drilling program at Lo Herma is now approved to proceed. The first phase of the program will target expansion of the resource base with a focus on extensions of the known trends to the north of planned mine units one and two. The program is targeting an increase of the current 8.57Mlbs (32% indicated) eU3O8Mineral Resource Estimate by converting Exploration Target Range mineralisation for Lo Herma which currently stands at 5.6 to 7.1 million tonnes at a grade range of 500 ppm to 700 ppm eU3O8. This work is expected to feed into an updated Mineral Resource Estimate and Scoping Study in 2026 positioning us to deliver value from America's nuclear energy revival."

The potential quantity and grade of the exploration target is conceptual in nature, there has been insufficient exploration to determine a mineral resource and there is no certainty that further exploration work will result in the determination of mineral resources.

Lo Herma Resource Development Drilling

As previously advised on 18 September 2025, AMU's drilling permit is for up to 121 drill hole locations with up to 37,500 metres (approximately 123,000 feet) of drilling.

The drilling is designed to achieve multiple objectives critical to advancing the Lo Herma Project. The primary goals include an initial phase of step-out drilling to target resource expansion to the north of both proposed MU1 and MU2, (Figure 1) where there is potential to increase the Project's overall resource base. A second phase of infill drilling is planned to upgrade Inferred Mineral Resources to Indicated or Measured category within MU1 and MU2, thereby increasing resource confidence.

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/D19Q15DL



About American Uranium Limited:

Lo Herma is American Uranium Limited's (ASX:AMU,OTC:GTRIF) (OTCMKTS:GTRIF) flagship and most advanced ISR uranium development project, leading our project portfolio and strong presence in Wyoming's Powder River Basin. Whilst Lo Herma is AMU's first priority, we also hold significant projects in Wyoming's Great Divide Basin/Green Mountain district and Utah's Henry Mountains with each offering potential for further growth across proven uranium districts. Located in Wyoming's premier uranium basin, the 13,500-acre Lo Herma project hosts a JORC compliant resource of 8.57 Mlb U3O8 with substantial growth potential. A recent positive Interim Scoping Study confirms low-cost development potential with drilling ready to expand and upgrade the resource. Surrounded by major ISR producers and backed by strategic investors, Lo Herma is well positioned to support America's future uranium supply independence.

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Smackover Lithium Releases Maiden Inferred Resource for its Franklin Project Comprising a Portion of Significant Brine Position in East Texas

Smackover Lithium Releases Maiden Inferred Resource for its Franklin Project Comprising a Portion of Significant Brine Position in East Texas

Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV: SLI) (NYSE.A: SLI) and Equinor ("Equinor") (OSE: EQNR) (NYSE: EQNR), announced today a maiden inferred resource for its Franklin Project (the "Project") in the northeast region of Texas, USA. This report for the JV's first project in the East Texas region of the Smackover highlights the size and quality of its brine position. It contains the highest reported lithium-in-brine grades in North America and marks a key step towards the ultimate goal of reaching production of over 100,000 tonnes of lithium chemicals per year in Texas through multiple phases. This goal is further supported by two additional projects that the JV is planning to develop in East Texas that roughly triples the size of the portfolio area in the state.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Standard Uranium Closes Second Tranche of Private Placement and Announces LIFE Offering

Standard Uranium Closes Second Tranche of Private Placement and Announces LIFE Offering

NOT FOR DISTRIBUTION TO UNITED STATES SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Standard Uranium Ltd. (TSXV: STND,OTC:STTDF) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce that it has closed a second tranche ("Tranche 2") of its non-brokered private placement (the "Private Placement Offering") for gross proceeds of $484,000.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News